This was a retrospective, cross-sectional exploratory analysis registered at the IRB (EKNr 1118/2018) and performed in accordance with the ethical standards stated in the Declaration of Helsinki. The research received no specific grant from any funding agency in the public, commercial, or nonprofit sectors. We reviewed OCTA images recorded with the Zeiss Plex Elite 9000 (Carl Zeiss Meditec AG, Jena, Germany) between July and November 2017 at the tertiary eye care center (Department of Ophthalmology, Medical University of Vienna, Austria). The SS OCTA device used operates at a center wavelength spectrum between 1040 and 1060 nm recording 100,000 A-scans per second to acquire OCTA volumes consisting of 500 × 500 A-scans and two frames per B-scan over an area of up to 12 × 12 mm. We included only images of good quality (9/10 or 10/10) and free from imaging artifacts that displayed lesions secondary to panretinal laser photocoagulation in the enface OCT fundus image. Scanning pattern were 12 × 12 mm centered on the fovea and 6 × 6 mm centered below the optic nerve head. Laser scars from focal or grid laser were not analyzed. Panretinal laser treatment had either been done with a conventional argon laser (Supra; Quantel Medical, Cournon d'Auvergne, France) or with the PAtterned SCAnning Laser (PASCAL; OptiMedica Corp., Santa Clara, CA, USA) system. PASCAL, a semi-automated neodymium-doped yttrium-aluminum-garnet laser, employs a shorter pulse duration of 10 to 20 ms compared to 100 to 200 ms in conventional argon laser. Both systems emit green light at a wavelength of 532 nm. Patient charts were reviewed to identify patients with diabetes and variables such as age, sex, A1c level, diabetes type and duration, history of anti-VEGF injections or vitreoretinal surgery, time since panretinal laser treatment, number of applied laser spots and the laser device used were recorded.